186 related articles for article (PubMed ID: 35538309)
1. Neuroendocrine neoplasms of the ovary: an analysis of clinicopathological characteristics and prognosis with a focus on histological grading.
Huang W; Bao Y; Luo X; Yao L; Yuan L
Endocrine; 2022 Jun; 77(1):188-198. PubMed ID: 35538309
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary.
Zhu Y; Meng F; Fang H; Zhang Z; Wang L; Zheng W
Int J Gynecol Cancer; 2020 Feb; 30(2):207-212. PubMed ID: 31796530
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine neoplasms of the ovary: a review of 63 cases.
Flores Legarreta A; Saab R; Gonzales NR; Chisholm GB; Westin SN; Hillman RT; Frumovitz M
Int J Gynecol Cancer; 2024 Apr; 34(4):566-573. PubMed ID: 38290783
[TBL] [Abstract][Full Text] [Related]
4. Case series of ovarian neuroendocrine carcinoma: overview of clinicopathological features.
Feng BJ; Li TH; Li YH; Feng JX; Zhang J; Ma JY; Wang YW; Lu SS
BMC Womens Health; 2023 Nov; 23(1):595. PubMed ID: 37953251
[TBL] [Abstract][Full Text] [Related]
5. Primary neuroendocrine tumors of the ovary: Management and outcomes.
Pang L; Guo Z
Cancer Med; 2021 Dec; 10(23):8558-8569. PubMed ID: 34773393
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance for colorectal carcinoid tumors based on the 8th edition TNM staging system.
Gong P; Chen C; Wang Z; Zhang X; Hu W; Hu Z; Li X
Cancer Med; 2020 Nov; 9(21):7979-7987. PubMed ID: 32897004
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.
Gibbs J; Mei S; Economos K; Lee YC; Kanis MJ
Am J Obstet Gynecol; 2019 Jul; 221(1):53.e1-53.e6. PubMed ID: 30849352
[TBL] [Abstract][Full Text] [Related]
8. A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes.
Ishikawa M; Kasamatsu T; Tsuda H; Fukunaga M; Sakamoto A; Kaku T; Kato T; Takahashi K; Ariyoshi K; Suzuki K; Arimoto T; Matsumoto Y; Nakai H; Inoue T; Yokoyama M; Kawabata T; Kodama S; Miyamoto T; Takano M; Yaegashi N
Gynecol Oncol; 2019 Dec; 155(3):444-451. PubMed ID: 31635755
[TBL] [Abstract][Full Text] [Related]
9. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
Feng M; Zou J; Zhang Y; Sun L
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
[No Abstract] [Full Text] [Related]
10. Two cases of lung neuroendocrine carcinoma with carcinoid morphology.
Inafuku K; Yokose T; Ito H; Eriguchi D; Samejima J; Nagashima T; Nakayama H; Suzuki M; Yamada K; Masuda M
Diagn Pathol; 2019 Sep; 14(1):104. PubMed ID: 31511024
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic Features and Survival Outcomes for Primary Renal Neuroendocrine Neoplasms.
Yi Z; Liu R; Hu J; He T; Wang Z; Li Y; Zu X
Clin Genitourin Cancer; 2021 Apr; 19(2):155-161. PubMed ID: 33288452
[TBL] [Abstract][Full Text] [Related]
12. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast.
Cloyd JM; Yang RL; Allison KH; Norton JA; Hernandez-Boussard T; Wapnir IL
Breast Cancer Res Treat; 2014 Dec; 148(3):637-44. PubMed ID: 25399232
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
14. Lung neuroendocrine neoplasms: a single centre surgical series and analysis of staging.
Davies RA; Alam NZ; Wright GM
ANZ J Surg; 2023 Jun; 93(6):1543-1550. PubMed ID: 37106553
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
[TBL] [Abstract][Full Text] [Related]
16. The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.
Xu B; Chu Y; Hu Q; Song Q
Technol Cancer Res Treat; 2021; 20():15330338211055340. PubMed ID: 34806493
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
18. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic analysis of colon and rectal neuroendocrine neoplasm in different stages].
Huang YT; Jia R; Xu Q; Ji SJ; Cui HT; Xu JM
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):146-151. PubMed ID: 30862146
[No Abstract] [Full Text] [Related]
20. Clinicopathological Features, Prognostic Factors, Survival Trends, and Treatment of Malignant Ovarian Germ Cell Tumors: A SEER Database Analysis.
Guo H; Chen H; Wang W; Chen L
Oncol Res Treat; 2021; 44(4):145-153. PubMed ID: 33706324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
